⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SYRE News
Spyre Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
SYRE
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
globenewswire.com
SYRE
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
SYRE